312 related articles for article (PubMed ID: 18060073)
1. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
Estep AL; Palmer C; McCormick F; Rauen KA
PLoS One; 2007 Dec; 2(12):e1279. PubMed ID: 18060073
[TBL] [Abstract][Full Text] [Related]
2. Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.
Rodriguez-Viciana P; Rauen KA
Methods Enzymol; 2008; 438():277-89. PubMed ID: 18413255
[TBL] [Abstract][Full Text] [Related]
3. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Activating Mutations of the
Borrelli N; Panebianco F; Condello V; Barletta JA; Kaya C; Yip L; Nikiforova MN; Nikiforov YE
Thyroid; 2019 Sep; 29(9):1279-1285. PubMed ID: 31407636
[No Abstract] [Full Text] [Related]
5. Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.
Dentici ML; Sarkozy A; Pantaleoni F; Carta C; Lepri F; Ferese R; Cordeddu V; Martinelli S; Briuglia S; Digilio MC; Zampino G; Tartaglia M; Dallapiccola B
Eur J Hum Genet; 2009 Jun; 17(6):733-40. PubMed ID: 19156172
[TBL] [Abstract][Full Text] [Related]
6. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
Nyström AM; Ekvall S; Berglund E; Björkqvist M; Braathen G; Duchen K; Enell H; Holmberg E; Holmlund U; Olsson-Engman M; Annerén G; Bondeson ML
J Med Genet; 2008 Aug; 45(8):500-6. PubMed ID: 18456719
[TBL] [Abstract][Full Text] [Related]
7. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
[TBL] [Abstract][Full Text] [Related]
8. Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome.
Gripp KW; Lin AE; Nicholson L; Allen W; Cramer A; Jones KL; Kutz W; Peck D; Rebolledo MA; Wheeler PG; Wilson W; Al-Rahawan MM; Stabley DL; Sol-Church K
Am J Med Genet A; 2007 Jul; 143A(13):1472-80. PubMed ID: 17551924
[TBL] [Abstract][Full Text] [Related]
9. MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Emery CM; Vijayendran KG; Zipser MC; Sawyer AM; Niu L; Kim JJ; Hatton C; Chopra R; Oberholzer PA; Karpova MB; MacConaill LE; Zhang J; Gray NS; Sellers WR; Dummer R; Garraway LA
Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20411-6. PubMed ID: 19915144
[TBL] [Abstract][Full Text] [Related]
10. Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations.
Rauen KA; Tidyman WE; Estep AL; Sampath S; Peltier HM; Bale SJ; Lacassie Y
Am J Med Genet A; 2010 Apr; 152A(4):807-14. PubMed ID: 20358587
[TBL] [Abstract][Full Text] [Related]
11. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
Nikolaev SI; Rimoldi D; Iseli C; Valsesia A; Robyr D; Gehrig C; Harshman K; Guipponi M; Bukach O; Zoete V; Michielin O; Muehlethaler K; Speiser D; Beckmann JS; Xenarios I; Halazonetis TD; Jongeneel CV; Stevenson BJ; Antonarakis SE
Nat Genet; 2011 Dec; 44(2):133-9. PubMed ID: 22197931
[TBL] [Abstract][Full Text] [Related]
12. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
Rodriguez-Viciana P; Tetsu O; Tidyman WE; Estep AL; Conger BA; Cruz MS; McCormick F; Rauen KA
Science; 2006 Mar; 311(5765):1287-90. PubMed ID: 16439621
[TBL] [Abstract][Full Text] [Related]
14. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
Hong SK; Wu PK; Karkhanis M; Park JI
Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
[TBL] [Abstract][Full Text] [Related]
15. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
16. Mutational and functional analysis in human Ras/MAP kinase genetic syndromes.
Tidyman WE; Rauen KA
Methods Mol Biol; 2010; 661():433-47. PubMed ID: 20812000
[TBL] [Abstract][Full Text] [Related]
17. Familial cardio-facio-cutaneous syndrome: Vertical transmission of the BRAF p.G464R pathogenic variant and review of the literature.
Rauen KA; Maeda Y; Egense A; Tidyman WE
Am J Med Genet A; 2021 Feb; 185(2):469-475. PubMed ID: 33274568
[TBL] [Abstract][Full Text] [Related]
18. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
19. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H
Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
